| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDW350 |
| P698 | PubMed publication ID | 27664260 |
| P50 | author | David Cunningham | Q38803238 |
| Dirk Arnold | Q54285507 | ||
| Elizabeth C Smyth | Q82087786 | ||
| ESMO Guidelines Committee | Q98803495 | ||
| P2093 | author name string | A Cervantes | |
| M Verheij | |||
| W Allum | |||
| P433 | issue | suppl 5 | |
| P304 | page(s) | v38-v49 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| P478 | volume | 27 |
| Q58693604 | A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy |
| Q49645479 | A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer |
| Q64231167 | A Proposal of a Personalized Surveillance Strategy for Gastric Cancer: A Retrospective Analysis of 9191 Patients |
| Q89861887 | A SOX2 Reporter System Identifies Gastric Cancer Stem-Like Cells Sensitive to Monensin |
| Q55091056 | A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. |
| Q60934019 | A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial |
| Q64966235 | Accuracy of endoscopic ultrasound in gastric adenocarcinoma patient selection for neoadjuvant therapy. |
| Q57069558 | Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study |
| Q104459144 | An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer |
| Q52583991 | Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. |
| Q92557676 | COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis |
| Q58755544 | CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in re |
| Q91651642 | CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis |
| Q89418193 | CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA |
| Q93136712 | Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers |
| Q99551756 | Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer |
| Q58772581 | Characterization of an orthotopic gastric cancer mouse model with lymph node and organ metastases using bioluminescence imaging |
| Q90012529 | Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases |
| Q98177944 | Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer |
| Q45324790 | Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal. |
| Q88801590 | Clinical impact of molecular classifications in gastric cancer |
| Q104617775 | Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies |
| Q90437266 | Clinical scoring system for the prediction of survival of patients with advanced gastric cancer |
| Q88574726 | Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis |
| Q55400693 | Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. |
| Q89949906 | Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer |
| Q64107299 | Contemporary paradigm for the evaluation and treatment of hereditary gastric cancer |
| Q55514438 | Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. |
| Q38985204 | Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. |
| Q90319007 | Current status of adjuvant chemotherapy for gastric cancer |
| Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers. |
| Q96298084 | D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature |
| Q90433471 | Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group |
| Q101149167 | Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States |
| Q90344467 | Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes |
| Q64117570 | Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer |
| Q64234118 | Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer |
| Q55117181 | Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. |
| Q64255358 | Double Contrast-Enhanced Ultrasonography in Preoperative T Staging of Gastric Cancer: A Comparison With Endoscopic Ultrasonography |
| Q91895820 | Downregulated Expression of hsa_circ_0005556 in Gastric Cancer and Its Clinical Significance |
| Q90016120 | Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report |
| Q64284309 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction |
| Q39385044 | Early postoperative imaging after non-bariatric gastric resection: a primer for radiologists |
| Q57288689 | Effect of hospital and surgeon volume on postoperative outcomes after distal gastrectomy for gastric cancer based on data from 145,523 Japanese patients collected from a nationwide web-based data entry system |
| Q92223933 | Effect of laparoscopic vs. open distal gastrectomy on 3-year disease free survival in patients with locally advanced gastric cancer: commentary on the class-01 randomized clinical trial |
| Q89896150 | Effects of Helix Geometry on Magnetic Guiding of Helical Polymer Composites on a Gastric Cancer Model: A Feasibility Study |
| Q92835208 | Effects of propofol and sevoflurane on blood glucose, hemodynamics, and inflammatory factors of patients with type 2 diabetes mellitus and gastric cancer |
| Q64952998 | Efficacy and Safety of Xiao Ai Ping Injection Combined with Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. |
| Q89001806 | Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study |
| Q47771553 | Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice |
| Q92091348 | Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage |
| Q52668202 | Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. |
| Q57111080 | Emerging Therapies in the Management of Advanced-Stage Gastric Cancer |
| Q64232920 | Endoscopic ultrasonography for pretreatment T-staging of gastric cancer: An accuracy and discrepancy analysis |
| Q52802735 | Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. |
| Q92006611 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction canc |
| Q41376426 | Expression and Clinical Significance of ILF2 in Gastric Cancer. |
| Q103755974 | Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial |
| Q90053012 | Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients |
| Q89585735 | FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer |
| Q55357371 | Favoring D2-Lymphadenectomy in Gastric Cancer. |
| Q42347265 | Follow-up after curative resection for gastric cancer: Is it time to tailor it? |
| Q39343374 | Gastric adenocarcinoma. |
| Q99622843 | Gastric cancer |
| Q60924983 | Genomic loss of heterozygosity and survival in the REAL3 trial |
| Q92147431 | Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study |
| Q92241733 | How I treat gastric adenocarcinoma |
| Q98159631 | Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin |
| Q89795555 | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives |
| Q64939865 | Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. |
| Q91793873 | Imaging strategies in the management of gastric cancer: current role and future potential of MRI |
| Q92636993 | Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis |
| Q97643978 | Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives |
| Q99564954 | Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer |
| Q47648562 | Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial |
| Q54249564 | Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion. |
| Q64091112 | Impact of spleen-preserving total gastrectomy on postoperative infectious complications and 5-year overall survival: systematic review and meta-analysis of contemporary randomized clinical trials |
| Q64226733 | Impact of time from diagnosis to chemotherapy in advanced gastric cancer: A Propensity Score Matching Study to Balance Prognostic Factors |
| Q64065039 | Implementation of endoscopic submucosal dissection for early upper gastrointestinal tract cancer after primary experience in colorectal endoscopic submucosal dissection |
| Q88992191 | Improvement of recovery parameters using patient-controlled epidural analgesia after oncological surgery. A prospective, randomized single center study |
| Q112278043 | In Silico Identification of Hub Genes as Observing Biomarkers for Gastric Cancer Metastasis |
| Q93335859 | Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis |
| Q64069303 | Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data |
| Q89538394 | Knockdown of ATAD2 Inhibits Proliferation and Tumorigenicity Through the Rb-E2F1 Pathway and Serves as a Novel Prognostic Indicator in Gastric Cancer |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q93135012 | Late-line treatment in metastatic gastric cancer: today and tomorrow |
| Q64064539 | Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients |
| Q57130345 | Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab |
| Q89312954 | Lymphadenectomy: state of the art |
| Q92990086 | Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin |
| Q64993818 | MiR-99b-5p and miR-203a-3p Function as Tumor Suppressors by Targeting IGF-1R in Gastric Cancer. |
| Q91742526 | MicroRNA-143 suppresses the proliferation and metastasis of human gastric cancer cells via modulation of STAT3 expression |
| Q92890164 | MicroRNA-761 inhibits the metastasis of gastric cancer by negatively regulating Ras and Rab interactor 1 |
| Q59812726 | Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake |
| Q64903597 | Modularized laparoscopic regional en bloc mesogastrium excision (rEME) based on membrane anatomy for distal gastric cancer. |
| Q64087363 | Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis |
| Q53821735 | Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center. |
| Q64060776 | Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling |
| Q47146995 | Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature |
| Q89883680 | Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population |
| Q47745009 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q96348662 | Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy |
| Q88616304 | Oesophageal cancer |
| Q64934996 | Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. |
| Q93023155 | Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study |
| Q97423269 | PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2 |
| Q89823493 | PVT1 Long Non-coding RNA in Gastrointestinal Cancer |
| Q90247411 | Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability |
| Q53707065 | Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. |
| Q92619104 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study |
| Q89029141 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial |
| Q64971797 | Peri-Operative Blood Transfusion Does Not Influence Overall and Disease-Free Survival After Radical Gastrectomy for Stage II/III Gastric Cancer: a Propensity Score Matching Analysis. |
| Q38645728 | Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. |
| Q64064533 | Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions |
| Q91456012 | Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study |
| Q90264677 | Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial |
| Q90568939 | Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 |
| Q57792975 | Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma |
| Q92384101 | Postoperative Radiotherapy Improves Survival in Gastric Signet-Ring Cell Carcinoma: a SEER Database Analysis |
| Q89533896 | Potential value of CT radiomics in the distinction of intestinal-type gastric adenocarcinomas |
| Q55395097 | Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia. |
| Q88136015 | Precision medicine in the adjuvant treatment of gastric cancer |
| Q57126061 | Preoperative Nodal F-FDG Avidity Rather than Primary Tumor Avidity Determines the Prognosis of Patients with Advanced Gastric Cancer |
| Q90257564 | Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from t |
| Q92801850 | Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability |
| Q58793479 | Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol |
| Q92199949 | Radiomics approaches in gastric cancer: a frontier in clinical decision making |
| Q91338868 | Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q56967468 | Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer |
| Q92324358 | Recent progress of chemotherapy and biomarkers for gastroesophageal cancer |
| Q93334976 | Recommendations on the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19 |
| Q55690221 | Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. |
| Q48569564 | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. |
| Q90814281 | Regulation of aberrantly expressed SERPINH1 by antitumor miR-148a-5p inhibits cancer cell aggressiveness in gastric cancer |
| Q89809809 | Retrospective imaging studies of gastric cancer: Study protocol clinical trial (SPIRIT Compliant) |
| Q58806085 | Role of lymph node ratio in selection of adjuvant treatment (chemotherapy chemoradiation) in patients with resected gastric cancer |
| Q92835307 | Routine chest CT for staging of gastric cancer |
| Q64289746 | Routinely staging gastric cancer with F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery |
| Q64966949 | S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. |
| Q97589307 | S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial |
| Q92310363 | Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil |
| Q53837214 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. |
| Q92897463 | Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial |
| Q91713198 | Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202) |
| Q65000653 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II tr |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q98181145 | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry |
| Q90141978 | Simultaneous determination of gastric cancer biomarkers pepsinogen PGI/PGII using element tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection |
| Q92390496 | Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment |
| Q64973847 | Surgery with curative intent for stage IV gastric cancer: Is it a reality of illusion? |
| Q54695199 | Survival benefit of "D2-plus" gastrectomy in gastric cancer patients with duodenal invasion. |
| Q64978235 | Targeted literature review of the global burden of gastric cancer. |
| Q92408693 | Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies |
| Q64078991 | The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer |
| Q61795899 | The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis |
| Q89967122 | The Methods of Lymph Node Examination Make a Difference to Node Staging and Detection of N3b Node Status for Gastric Cancer |
| Q94526793 | The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy |
| Q97074390 | The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication |
| Q49970732 | The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer |
| Q91727286 | The Role of the Lymph Node Ratio in Advanced Gastric Cancer After Neoadjuvant Chemotherapy |
| Q90423541 | The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers |
| Q90053624 | The Use of (Network) Meta-Analysis in Clinical Oncology |
| Q89771361 | The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy |
| Q91838151 | The impact of TP53BP1 and MLH1 on metastatic capability in cases of locally advanced prostate cancer and their usefulness in clinical practice |
| Q90660013 | The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY) |
| Q33621706 | The value of staging laparoscopy in gastric cancer |
| Q55330265 | Translational research and application of basic biology to clinical trial development in GI cancers. |
| Q47100522 | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. |
| Q64109771 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study |
| Q47678852 | Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study |
| Q92199816 | Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy |
| Q93138804 | Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer |
| Q57812653 | Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q50197856 | Tumor budding as a standardized parameter in gastrointestinal carcinomas: more than just the colon |
| Q90695337 | Two steps forward and one step back |
| Q92648749 | Upregulated RACK1 attenuates gastric cancer cell growth and epithelial-mesenchymal transition via suppressing Wnt/β-catenin signaling |
| Q89823531 | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study |
| Q91468491 | Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer |
| Q90437242 | Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome |
| Q57159608 | What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives |
| Q91911733 | XEDAR inhibits the proliferation and induces apoptosis of gastric cancer cells by regulating JNK signaling pathway |
| Q89815247 | [Therapeutic approach in oligometastatic gastric and esophageal cancer] |
| Q90007067 | [Therapeutic regimens using monoclonal antibodies in gastroenterology] |
| Q91789126 | miR-26a-5p Inhibit Gastric Cancer Cell Proliferation and Invasion Through Mediated Wnt5a |
Search more.